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Cost-eﬀ ectiveness of HIV prevention for high-risk groups 
at scale: an economic evaluation of the Avahan programme 
in south India
Anna Vassall, Michael Pickles, Sudhashree Chandrashekar, Marie-Claude Boily, Govindraj Shetty, Lorna Guinness, Catherine M Lowndes, 
Janet Bradley, Stephen Moses, Michel Alary, Charme India Group*, Peter Vickerman
Summary
Background Avahan is a large-scale, HIV preventive intervention, targeting high-risk populations in south India. 
We assessed the cost-eﬀ ectiveness of Avahan to inform global and national funding institutions who are considering 
investing in worldwide HIV prevention in concentrated epidemics.
Methods We estimated cost eﬀ ectiveness from a programme perspective in 22 districts in four high-prevalence states. 
We used the UNAIDS Costing Guidelines for HIV Prevention Strategies as the basis for our costing method, and 
calculated eﬀ ect estimates using a dynamic transmission model of HIV and sexually transmitted disease transmission 
that was parameterised and ﬁ tted to locally observed behavioural and prevalence trends. We calculated incremental 
cost-eﬀ ective ratios (ICERs), comparing the incremental cost of Avahan per disability-adjusted life-year (DALY) 
averted versus a no-Avahan counterfactual scenario. We also estimated incremental cost per HIV infection averted 
and incremental cost per person reached.
Findings Avahan reached roughly 150 000 high-risk individuals between 2004 and 2008 in the 22 districts studied, at a 
mean cost per person reached of US$327 during the 4 years. This reach resulted in an estimated 61 000 HIV infections 
averted, with roughly 11 000 HIV infections averted in the general population, at a mean incremental cost per HIV 
infection averted of $785 (SD 166). We estimate that roughly 1 million DALYs were averted across the 22 districts, at a 
mean incremental cost per DALY averted of $46 (SD 10). Future antiretroviral treatment (ART) cost savings during 
the lifetime of the cohort exposed to HIV prevention were estimated to be more than $77 million (compared with the 
slightly more than $50 million spent on Avahan in the 22 districts during the 4 years of the study).
Interpretation This study provides evidence that the investment in targeted HIV prevention programmes in south 
India has been cost eﬀ ective, and is likely to be cost saving if a commitment is made to provide ART to all that can 
beneﬁ t from it. Policy makers should consider funding and sustaining large-scale targeted HIV prevention 
programmes in India and beyond.
Funding Bill & Melinda Gates Foundation.
Copyright © Vassall et al. Open Access article distributed under the terms of CC BY-NC-ND.
Introduction
More than 2 million people are living with HIV in India.1 
The epidemic is concentrated and predominantly driven 
by high-risk groups, particularly female sex workers 
(FSWs) and their clients, men who have sex with men 
(MSM), and, in some contexts, injecting drug users.2 
The Avahan programme, the Indian AIDS initiative of 
the Bill & Melinda Gates Foundation, was one of the 
largest HIV prevention programmes targeted at high-
risk groups worldwide. Avahan operated across six 
Indian states and had a funding commitment of US$258 
million between 2004 and 2009.3 Avahan was 
implemented through state lead partners, who 
contracted a plethora of local non-governmental 
organisations (NGOs) at the district level. From Avahan’s 
inception, rigorous evaluation has been an integral part 
of the programme,4 including the assessment of cost-
eﬀ ectiveness.
Avahan has been shown to be eﬀ ective in the 
reduction of HIV transmission. In an evaluation that 
used a combination of detailed biobehavioural surveys 
and mathematical modelling in a subset of 22 of 83 total 
districts where it was implemented, medium to strong 
evidence of eﬀ ect was reported in most districts 
modelled, especially those with less condom use in 
commercial sex at the start of the intervention.5,6 Avahan 
averted 42% of all HIV infections during 4 years, 
corresponding to 68 000 (95% credibility interval 
32 000–202 000) cases averted in 22 modelled districts. 
In 10 years, this number increased to 214 000 
(99 000–373 000), representing 57% of HIV infections 
averted. Geographical extrapolation by use of a 
statistical regression model to all Avahan districts 
showed that 202 000 HIV infections were averted in 
4 years, increasing to 606 000 HIV infections averted in 
10 years.6
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However, Avahan also incurred substantial costs.7 
Hence, HIV policy makers need to know whether the 
programme was also cost eﬀ ective to inform decisions 
about making sizeable investments in HIV prevention at 
scale in other similar settings, especially at a time when 
HIV programmes are facing increasing demands on 
their scarce resources. So far, few robust studies have 
investigated the cost-eﬀ ectiveness of HIV prevention 
targeted at high-risk groups, with only a handful done in 
Asia.8 The most comprehensive estimate so far suggested 
a potential incremental cost per DALY averted of US$10.9,7 
However, great uncertainty remains around these 
predictions, with a 30% chance that HIV prevention for 
FSWs would not be cost eﬀ ective.9,7
Several small project-based studies also suggest that 
cost-eﬀ ectiveness could be achieved.10–12 However, these 
studies exclude the costs of the substantial eﬀ ort associated 
with large-scale implementation.10 Previous studies also 
did not have the beneﬁ ts of extensive target population 
surveys, did not use dynamic eﬀ ect estimates, excluded 
heterogeneity in FSW risk behaviour, and did not ﬁ t the 
eﬀ ect model to time trends in HIV prevalence.11,12 In view 
of this evidence gap and the increasing scarce resources 
for HIV prevention, we did a large-scale economic 
evaluation of Avahan to examine whether HIV prevention 
for high-risk groups could achieve cost-eﬀ ectiveness in 
the real world and at scale, and whether it should thus be 
sustained as a priority investment for global public health.
Methods
Study design
We estimated the cost-eﬀ ectiveness of Avahan from a 
provider perspective. Our primary measure is the 
incremental cost eﬀ ective ratio (ICER), comparing the 
incremental cost per DALY averted versus a no-Avahan 
counterfactual base case. Secondary measures include 
incremental cost per HIV infection averted and 
incremental cost per person reached.
We classiﬁ ed HIV prevention as cost eﬀ ective a priori if 
the incremental cost per DALY averted was less than the 
gross domestic product (GDP) per head in 2011 
(US$1500).13 HIV prevention was classiﬁ ed as cost saving 
if the costs of antiretroviral treatment (ART) during the 
lifetime of the cohort of individuals exposed to HIV 
prevention during the ﬁ rst 4 years of the programme 
outweighed the costs spent in the ﬁ rst 4 years of the 
programme. Our primary ICER and cost-savings 
estimates assume that all future costs and DALYS averted 
are discounted at a 3% rate.
Programme and study setting
We evaluated HIV prevention activities in 22 districts in 
four of the six Indian states considered to have high HIV 
prevalence (Andhra Pradesh [0·9%], Karnataka [0·6%], 
Maharashtra [0·6%], and Tamil Nadu [0·3%] in 2009).14 
With time, HIV prevalence has shown a declining trend 
in all four states.14 However, the number of people living 
with HIV remains high, with Andhra Pradesh having 
500 000 people living with HIV followed by Maharashtra 
(420 000), Karnataka (250 000), and Tamil Nadu (150 000) 
in 2011.14
The Avahan programme contracted grantees at the state 
level (state lead partners) to work with grass-root NGOs to 
deliver a package of services to both FSW and MSM 
populations in these states.3,15 The standard package 
implemented by NGOs includes peer-led outreach, 
education and condom distribution, free treatment of 
sexually transmitted infections (STIs) through project-
operated clinical services or through preferred service 
providers, free commodity supplies (condoms, STI 
drugs), and facilitation of community mobilisation. Peer 
educators promoted condom use and attendance at 
clinics, and encouraged follow-up and partner treatment. 
Clinics provided treatment for STIs, referred clients to 
other clinical services, including HIV and tuberculosis 
testing, or both, and provided HIV treatment and care. 
Additional grantees did other activities such as capacity-
building, social marketing, trucker programmes, 
national-level and state-level advocacy, and knowledge-
building activities, across each state and nationally.3,16
Cost estimation
The UNAIDS Costing Guidelines for HIV Prevention 
Strategies were taken as the basis for the costing 
method.17 Economic costs were estimated for every 
organisation level: NGO, state lead partners, and the 
national programme oﬃ  ce for every year between 2004 
and 2008 in all 22 districts, as part of a larger study into 
68 districts across the four Indian states. A full 
description of methods and the presentation of the cost 
data used are publicly available.7 We did not cost the no-
Avahan counterfactual because of insuﬃ  cient data 
availability at baseline. This approach implicitly assumes 
that the full cost of Avahan was required to achieve the 
diﬀ erences in condom use achieved by Avahan over and 
above the counterfactual base case. To aid comparability 
with other studies, our results are presented in two 
categories: NGO costs (costs incurred at the NGO level 
only) and programme costs, including costs incurred at 
the state lead partners and national level (these include 
activities such as programme management, expertise 
enhancement [capacity building], and community 
supply costs).
Total and unit costs were estimated with data for 
expenditure, resource use, and activity that were obtained 
from routine reporting, and from staﬀ  records and 
interviews during the period 2004–08. Details of donated 
goods and services were collected from every district and 
were valued at market prices. Start-up and training costs 
were annualised during the lifetime of the project 
(assumed to be 5 years). The start-up period was deﬁ ned 
as project inception until the start of service delivery to 
the target population. Costs of the evaluation and 
research activities were excluded.
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Personnel costs covered the salaries and expenses of all 
staﬀ , including peer educators, volunteers, and shared 
resource personnel. Peer educator time was valued at the 
honorarium paid, except when not paid. In the latter 
case, and for other volunteers, time costs were valued 
using self-reported average earnings or, if unemployed, 
the payment made to peers in interventions undertaken 
by the National Aids Control Organisation (NACO), 
Government of India. Condom costs (where provided to 
the programme for free) were estimated with the lowest-
priced market alternative. The Bill & Melinda Gates 
Foundation costs were allocated to state lead partners 
according to the size of the grant during the year of 
analysis, on the basis of interviews with programme 
staﬀ . State lead partners’ costs were allocated to each of 
the 22 districts after extensive interviews. The ﬁ rst stage 
in allocation was to apportion every cost that was reported 
in expenditure records as being allocated to a speciﬁ c (or 
group of) NGOs. On the basis of the interviews, any 
remainder of costs that could be clearly associated with 
programme management was allocated to each NGO on 
an equal basis. All remaining costs (mainly those that 
related to service provision levels) were allocated 
according to estimated population size, because this was 
used by state lead partners to assess and approve 
budgetary levels for other activities. These state lead 
partners’ costs were combined with NGO expenditures to 
estimate the costs of diﬀ erent activities based on a 
combination of interviews, actual use, and for personnel 
costs on the basis of time sheets.
To estimate potential cost savings, we sourced ART 
costs from the literature (table 1). Data for the costs of 
ART in India are insuﬃ  cient. The costs used do not 
include the full cost of treatment of opportunistic 
infections, or costs to maintain adherence with time, and 
therefore it is highly likely that our estimates of cost 
savings are conservative.
Unit costs were calculated per number of people 
reached at least once in a year, measured with data from 
the programme management information system. The 
quality of management information system data 
developed through the time period. Although all NGOs 
in this studied reported key indicators from start-up in 
the ﬁ rst year, data quality was not checked by any central 
authority. Thereafter as the system was computerised, all 
data were checked, and any inconsistencies were fed 
back to NGOs for correction. Although this was done 
retrospectively for the ﬁ rst year data, staﬀ  interviewed at 
the Bill & Melinda Gates Foundation suggested there was 
some under-reporting in the ﬁ rst year, and thus early 
unit costs might overestimate the cost per person 
reached. All data were converted to US$ 2011 prices with 
the GDP deﬂ ator index,27 and the average exchange rate 
in the year of data collection.28 Further details of the 
costing methods and data (including cost breakdowns 
between inputs and activities) can be found in a study by 
Chandrashekar and colleagues.7
Eﬀ ect estimation
A purpose-built dynamic model of HIV/STI transmission 
was used to calculate HIV infections averted in FSWs, 
their clients, and MSM, and onward transmission to their 
long-term non-commercial partners, during the ﬁ rst 4 
and 10 years of the Avahan programme.6 All 22 districts 
with local biobehavioural surveys were modelled 
separately with probabilistic sampling methods. These 
districts were chosen to represent the geography and 
sociocultural characteristics of key populations across 
Avahan districts, with the district with the largest known 
sex worker population in every sociocultural region 
selected.29 Within the model, the intervention was 
assumed to have two eﬀ ects that directly drive impact: 
increasing condom use by FSW and enhancing STI 
treatment in clinics. Other intervention components such 
as structural interventions and community mobilisation 
were considered to act indirectly through increasing 
condom use and access to STI services.
The model used was dynamic (capturing indirect 
population-level eﬀ ects not included in cohort models) 
and was done within a Bayesian framework with detailed 
district-speciﬁ c data.30 This framework produced many 
parameter sets giving model ﬁ ts to prevalence data for 
HIV, herpes simplex virus 2, and syphilis, providing 
estimates of HIV infections averted with credibility 
intervals. The appendix provides additional information, 
and full details of the parameterisation and model and 
ﬁ tting methods used are described elsewhere.6
Model inputs
(values or sampling distributions)
Average duration of HIV stages (months)
Early HIV high viraemia phase Uniform (2·0, 6·0)18,19
Asymptomatic HIV infection Uniform (70·0, 91·0)18,19
Late-stage HIV infection Uniform (6·0, 18·0)18,19
AIDS phase without treatment Uniform (11·6, 29·4)18,19
DALY weight for early and asymptomatic HIV infection 020
DALY weight for late-stage HIV infection Truncated N (0·22, 0·0018)20
DALY weight for AIDS Truncated N (0·55, 0·0072)20
DALY weight on ART Truncated N (0·053, 0·00013)20
Life expectancy without HIV by age group (point estimates*)
25–29 years 43·8
30–34 years 39·3
35–39 years 34·9
40–44 years 30·7
45–49 years 26·5
50–54 years 22·6
Unit cost per person on ART per year (US$ 2011) Triangular (200, 400, 600)21
Extra life expectancy on ART if HIV positive (years) Triangular (5·9, 9·5, 26·0)22–25
Coverage of ART of eligible individuals (%) Uniform (21, 40)26
Truncated normal distributions truncated at 0 and 1. Triangular distributions speciﬁ ed by minimum, mode, and 
maximum values. DALY=disability adjusted life-year. ART=antiretroviral treatment. *WHO life expectancy tables, 2009. 
Table 1: Parameters sampled used to estimate infections and DALYs averted with uniform, truncated 
normal, and triangular distributions
For WHO life expectancy tables 
see http://apps.who.int/gho/
data/view.main.60740?lang=en’
See Online for appendix
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Trends in condom use with time were derived from 
survey data with a historical cohort method.31 To estimate 
incremental eﬀ ect due to Avahan in the absence of a 
control group, a simulated counterfactual scenario based 
on how condom use might have changed without the 
intervention was considered, for which condom use was 
also assumed to have continued to increase during the 
time-period of the intervention, but at the slower 
preintervention rate.5,6 This counterfactual scenario 
represents an extrapolation of what would have happened 
without Avahan, and allows for continued non-Avahan 
intervention and behaviour change. It is conservative 
because it assumes increased condom use even without 
Avahan. STI treatment was also assumed to continue at 
preintervention levels. Multiple parameter combinations 
that were found to be model ﬁ ts for the previously 
described intervention scenario were re-run for the 
counterfactual scenario to estimate the incremental 
infections averted, providing a range of estimates that 
were used in the cost-eﬀ ectiveness analysis.
Cost-eﬀ ectiveness analysis
We estimated ICERs for every district independently for 
4 year (2004–08) and 10-year (2004–14) time periods. The 
costs for the 10-year period are estimated with the costs 
per person reached in 2008 multiplied by the numbers 
of people reached up until 2014. This approach implicitly 
assumes no major changes in terms of service 
intervention and commodity prices beyond general price 
inﬂ ation with time. Disability-adjusted life-years (DALYs) 
averted were estimated from incremental infections 
averted generated by the eﬀ ect model, with standard 
formulae and disability weights for the lifetime of the 
cohort of people reached during 2004–08 (appendix). 
Our primary estimates use no age weighting. Table 1 
shows the parameters used in the cost eﬀ ectiveness 
analysis,18,19 which correspond with those used in several 
other HIV prevention cost-eﬀ ectiveness estimates for 
India,12 but not the previous national-level study that 
estimates DALYs averted during a 20-year time horizon.9
We also estimated cost savings from prevention of 
future ART costs. We assumed no additional preventive 
eﬀ ect from ART, because ART coverage in high-risk 
groups between 2004 and 2008 was extremely low,26 but 
focused on the potential cost savings in terms of future 
ART treatment, assuming diﬀ erent levels of future ART 
coverage. Table 1 shows survival assumptions and costs 
of ART. Notably, although ART increases survival time 
(and therefore reduces the DALYs averted from 
prevention of HIV intervention) it also substantially 
increases the costs of that survival. Data for ART costs in 
India are insuﬃ  cient, with most studies outdated and 
very little known about the costs of provision of ART to 
high-risk groups over a sustained period in diﬀ erent 
settings. We therefore chose a wide plausible range for 
cost of ﬁ rst-line treatment.
To estimate mean incremental NGO cost per DALY 
averted and mean incremental programme cost per 
DALY averted, we did a probabilistic sensitivity analysis 
in which we randomly sampled 50 000 combinations of 
all cost and DALY parameters, as well as model ﬁ ts, using 
uniform distributions. We created an acceptability curve 
to assist policy makers to interpret the uncertainty 
around cost-eﬀ ectiveness. Acceptability curves plot the 
probability that the intervention is cost eﬀ ective as the 
willingness-to-pay threshold changes. We also did one-
way sensitivity analyses for discount rates used to 
estimate DALYs averted (values 0%, 3%, and 8%) and 
future ART coverage (values 21–40% and 80%).
Role of the funding source
The funder of the study had no role in study design, data 
gathering, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all data and ﬁ nal responsibility for the decision to submit 
for publication.
Results
Table 2 shows the total costs for each of the 22 districts. 
About a third of the total cost of Avahan in these districts 
(US$50 533 660) was incurred at the NGO level 
($16 905 581) during 4 years. Avahan reached about 
154 425 high-risk group members between 2004 and 
NGO cost Total cost Total people 
reached
Mean NGO 
cost per person 
reached
Mean programme 
cost per person 
reached
Bangalore 2 684 630 5 810 706 23 567 114 247
Belgaum 680 639 1 503 305 8195 83 183
Chitoor 921 677 2 260 456 4315 214 524
E Godavari 120 438 566 278 4982 24 114
Guntur 1 089 054 3 778 974 19 905 55 190
Hyderabad 191 119 735 632 979 195 751
Karimnagar 705 576 1 528 325 6517 108 235
Kolhapur 216 858 780 358 1503 144 519
Madurai 1 057 745 2 774 012 7029 150 395
Parbhani 263 534 1 039 761 2448 108 425
Prakasham 470 766 1 963 486 6552 72 300
Pune 379 093 3 653 650 5617 67 650
Vizag 348 660 1 324 780 4895 71 271
Warangal 394 814 1 288 994 4593 86 281
Yevatmal 250 191 668 949 962 260 695
Mumbai 2 306 908 9 774 029 28 521 81 343
Chennai 1 084 134 2 828 183 6515 166 434
Coimbatore 655 441 1 585 553 4045 162 392
Dharmapuri 566 667 1 450 183 4125 137 352
Mysore 1 199 870 1 850 593 2021 594 916
Bellary 805 949 2 118 616 5030 160 421
Shimoga 511 820 1 248 836 2109 243 592
Total/mean 16 905 581 50 533 660 154 425 109 327
NGO=non-governmental organisation.
Table 2: NGO and programme cost per district and per person reached 2004–08 (US$ 2011)
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2008 in the 22 districts, at an NGO cost per person 
reached of $109 and a programme cost per person 
reached of $327. The cost per person reached diﬀ ered 
substantially between settings, with NGO costs ranging 
between $24 and $594 per person reached and total costs 
per person reached ranging between $114 and $916. 
Notably, some of the sites at the high end of the scale, 
such as Mysore, were so-called learning sites and had 
more investment than other districts to allow for the 
piloting of diﬀ erent intervention approaches.
A programme coverage of 154 425 high-risk group 
members during the 4-year period resulted in 61 744 HIV 
HIV infections averted Incremental cost per HIV infection averted 
(US$ 2011)
DALYs averted 
2004–08
Mean incremental cost per DALY averted (US$ 2011)
Total 2004–08 General 
population 
only 2004–08
NGO cost only 
2004–08
Total cost 
2004–08
Total cost 
2004–14
NGO cost only 
2004–08
Total cost 
2004–08
Total cost 
2004–14
Total cost 2004–08 
(0% discount)
Bangalore 3724
(1250–6197)
600
(104–1096)
721
(247-1195)
1561
(539–2582)
1265
(95–2436)
63 229
(21 435–105 023)
42
(14–71)
92
(31–153)
65
(3–127)
44
(15–73)
Belgaum 2084
(891–3277)
462
(163–761)
327
(131–522)
721
(291–1152)
810
(293–1327)
35 332
(15 037–55 628)
19
(8–31)
43
(17–68)
43
(15–71)
21
(8–33)
Chitoor 5977
(448–11 505)
1032
(0–2207)
154
(0–359)
378
(0–882)
208
(0–430)
104 616
7984–201 249)
9
(0–20)
22
(0–50)
10
(0–21)
10
(0–24)
E Godavari 1761
(1082–2440)
311
(142–480)
68
(41–96)
322
(195–448)
363
(200–527)
30 741
(18 715–42 768)
4
(2–6)
18
(11–26)
19
(10–27)
9
(5–12)
Guntur 8216
(4541–11 892)
1775
(942–2608)
133
(66–199)
460
(228–692)
556
(202–910)
138 362
(76 221–200 502)
8
(4–12)
27
(13–41)
30
(10–50)
13
(6–20)
Hyderabad 89
(0–286)
25
(0–75)
2139
(0–14 725)
8232
(0–56 754)
7736
(0–96 264)
1561
(0–4997)
122
(0–848)
471
(0–3269)
397
(0–5319)
221
(0–1540)
Karimnagar 4734
(2151–7316)
908
(260–1557)
149
(49–249)
323
(107–539)
291
(78–504)
82 831
(37 762–127 899)
9
(3–14)
18
(6–31)
15
(4–26)
9
(3–14)
Kolhapur 312
(0–952)
71
(0–222)
696
(NaN–NaN)
2501
(NaN–NaN)
3298
(0–113 140)
5454
(0–16 678)
40
(NaN–NaN)
143
(NaN–NaN)
171
(0–5935)
67
(NaN–NaN)
Madurai 10 025
(2748–17 302)
2053
(351–3755)
106
(5–206)
277
(14–540)
199
(56–342)
167 898
(44 226–291 570)
6
(0–12)
17
(1–32)
10
(3–18)
8
(0–16)
Parbhani 594
(0–1347)
101
(0–241)
444
(0–3773)
1752
(0–14 882)
1801
(0–29 466)
10 555
(0–23 973)
25
(0–213)
99
(0–841)
90
(0–1606)
45
(0–391)
Prakasham 1739
(509–2968)
266
(45–487)
271
(52–489)
1129
(220–2039)
684
(142–1225)
30 475
(8820–52 129)
15
(3–28)
64
(12–117)
34
(7–61)
30
(6–55)
Pune 520
(0–1130)
104
(0–247)
729
(0–4475)
7026
(0–43 092)
13453
(0–63 311)
9199
(0–20 102)
41
(0–250)
397
(0–2406)
722
(0–3344)
185
(0–1111)
Vizag 1492
(968–2017)
222
(84–360)
234
(151–316)
888
(580–1195)
1200
(721–1679)
27 004
(17 195–36 814)
13
(8–18)
49
(31–67)
60
(35–85)
22
(14–30)
Warangal 1330
(370–2290)
159
(22–296)
297
(69–524)
969
(227–1711)
1044
(0–2117)
23 098
(6535–39 661)
17
(4–30)
56
(13–98)
54
(0–110)
26
(6–47)
Yevatmal 1291
(244–2338)
280
(47–514)
194
(0–427)
518
(0–1141)
1300
(0–3229)
22 724
(4309–41 140)
11
(0–24)
29
(0–65)
71
(0–179)
14
(0–30)
Mumbai 1534
(0–3151)
328
(0–691)
1504
(0–4407)
6371
(0–18 685)
12 954
(0–32 693)
27 169
(0–55 770)
85
(0–249)
360
(0–1056)
702
(0–1749)
168
(0–482)
Chennai 1850
(434–3265)
258
(0–553)
586
(0–1197)
1529
(0–3118)
907
(0–2620)
32 244
(7591–56 898)
34
(0–69)
88
(0–181)
45
(0–136)
41
(0–84)
Coimbatore 3020
(0–6279)
456
(0–1069)
217
(0–489)
525
(0–1181)
318
(0–649)
52 426
(0–109 050)
13
(0–28)
30
(0–68)
16
(0–32)
14
(0–33)
Dharmapuri 4838
(272–9403)
891
(0–1999)
117
(0–255)
300
(0–651)
336
(0–748)
84 343
(4707–163 979)
7
(0–15)
17
(0–38)
18
(0–40)
8
(0–18)
Mysore 1694
(980–2409)
337
(134–541)
708
(407–1009)
1092
(628–1556)
949
(527–1370)
28 886
(16 676–41 097)
42
(24–59)
64
(36–92)
49
(27–72)
31
(17–44)
Bellary 4079
(1063–7096)
910
(179–1640)
198
(32–363)
519
(88–950)
495
(41–950)
68 990
(18 208–119 773)
12
(2–21)
31
(5–56)
26
(2–51)
15
(2–27)
Shimoga 862
(293–1431)
209
(54–364)
594
(137–1051)
1449
(336–2562)
911
(175–1646)
14 549
(4979–24 118)
35
(8–62)
86
(19–152)
47
(9–85)
41
(9–74)
Total 61 744
(48 908–74 580)
11 755
(8847–14 663)
263
(207–318)
785
(619–951)
692
(541–842)
1 061 255
(840 416–1 282 094)
15
(12–19)
46
(36–55)
36
(28–43)
22
(17–26)
Data are mean (SD 1·96). DALY=disability-adjusted life-year. NGO=non-governmental organisation. NaN=undeﬁ ned.
Table 3: Eﬀ ect and cost eﬀ ectiveness by district (unadjusted for future antiretroviral treatment costs)
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infections averted in total, with 11 755 HIV infections 
averted in the general population alone. The mean NGO 
cost per HIV infection averted was $263 and the mean 
programme cost per HIV infection averted was $785 
(table 3). When costs and eﬀ ect were extended for 
10 years, the mean programme cost per HIV infection 
averted fell to $692. Conversio of HIV infections averted 
into DALYs, we estimated that 1 061 255 DALYs were 
averted across the 22 districts, at a mean incremental 
NGO cost per DALY averted of US$15, and a mean 
incremental programme cost per DALY averted of $46 at 
a 3% discount rate without including ART cost savings. 
DALYs averted 
2004–08
Number of people on 
ART averted
Total cohort lifetime ART 
savings (US$ 2011)
Mean incremental cost per DALY averted (US$ 2011)
NGO cost 
2004–08
Total cost 
2004–08
Total cost 
2004–14
Total cost 2004–08 
(sensitivity analysis 80% 
ART coverage)
Bangalore 54 040
(17 721 to 90 359)
1135
(273 to 1997)
4 829 494
(–122 900 to 9 781 889)
Dom
(Dom to 41)
Dom
(Dom to 116)
Dom
(Dom to 92)
Dom
(Dom to 129)
Belgaum 30 130
(12 489 to 47 771)
636
(201 to 1071)
2 711 433
(66 035 to 5 356 830)
Dom
(Dom to 12)
Dom
(Dom to 41)
Dom
(Dom to 45)
Dom
(Dom to 69)
Chitoor 89 715
(6357 to 173 073)
1822
(0 to 3647)
7 792 459
(–2 092 675 to 17 677 592)
Dom
(Dom to 1)
Dom
(Dom to 20)
Dom
(Dom to 4)
Dom
(Dom to 31)
E Godavari 26 364
(15 688 to 37 039)
537
(253 to 822)
2 289 596
(304 361 to 4 274 831)
Dom Dom
(Dom to 10)
Dom
(Dom,12)
Dom
(Dom to 29)
Guntur 117 984
(63 190 to 172 779)
2503
(1082 to 3925)
10 679 678
(1 084 848 to 20 274 509)
Dom Dom
(Dom to 21)
Dom
(Dom to 26)
Dom
(Dom to 50)
Hyderabad 1339
(0 to 4295)
27
(0 to 88)
116 214
(–169 528 to 401 956)
Dom
(Dom to 906)
463
(Dom to 3740)
385
(Dom to 6149)
441
(Dom to 5110)
Karimnagar 71 079
(31 601 to 110 557)
1444
(492 to 2396)
6 151 329
(236 447 to 12 066 211)
Dom
(Dom to 0)
Dom
(Dom to 11)
Dom
(Dom to 8)
Dom
(Dom to 29)
Kolhapur 4668
(0 to 14 288)
96
(0 to 299)
407 737
(–539 623 to 1 355 098)
Dom
(NaN to NaN)
80
(NaN to NaN)
121
(Dom to 6869)
Dom
(NaN to NaN)
Madurai 143 169
(36 395 to 249 943)
3059
(555 to 5562)
13 056 142
(–1275 073 to 27 387 356)
Dom Dom
(Dom to 10)
Dom
(Dom to 3)
Dom
(Dom to 37)
Parbhani 9079
(0 to 20 649)
182
(0 to 427)
773 278
(–458 898 to 2 005 454)
Dom
(Dom to 174)
29
(Dom to 903)
29
(Dom to 1801)
Dom
(Dom to 1086)
Prakasham 26 143
(7366 to 44 920)
530
(105 to 956)
2 264 163
(–188 251 to 4 716 577)
Dom
(Dom to 8)
Dom
(Dom to 81)
Dom
(Dom to 34)
Dom
(Dom to 88)
Pune 7905
(0 to 17 317)
159
(0 to 357)
673 993
(–312 244 to 1 660 230)
Dom
(Dom to 215)
377
(Dom to 2728)
759
(Dom to 3830)
325
(Dom to 3640)
Vizag 23 285
(14 494 to 32 075)
455
(226 to 684)
1 941 814
(272 408 to 3 611 220)
Dom
(Dom to 4)
Dom
(Dom to 45)
Dom
(Dom to 61)
Dom
(Dom to 55)
Warangal 19 776
(5457 to 34 095)
405
(75 to 736)
1 728 117
(–148 578 to 3 604 812)
Dom
(Dom to 10)
Dom
(Dom to 64)
Dom
(Dom to 75)
Dom
(Dom to 79)
Yevatmal 19 524
(3558 to 35 491)
394
(41 to 746)
1 678 688
(–260 446 to 3 617 822)
Dom
(Dom to 3)
Dom
(Dom to 31)
0
(Dom to 140)
Dom
(Dom to 42)
Mumbai 23 335
(0 to 47 972)
468
(0 to 996)
1 995 413
(–735 688 to 4 726 513)
Dom
(Dom to 216)
333
(Dom to 1145)
735
(Dom to 1956)
266
(Dom to 1397)
Chennai 27 656
(6259 to 49 052)
563
(87 to 1040)
2 406 104
(–282 164 to 5 094 371)
Dom
(Dom to 37)
15
(Dom to 143)
Dom
(Dom to 98)
Dom
(Dom to 143)
Coimbatore 44 879
(0 to 93 673)
921
(0 to 1985)
3 917 035
(–1 426 947 to 9 261 016)
Dom
(Dom to 6)
Dom
(Dom to 34)
Dom
(Dom to 11)
Dom
(Dom to 49)
Dharmapuri 72 298
(3482 to 141 115)
1477
(0 to 2986)
6 290 088
(–1 618 884 to 14 199 061)
Dom Dom
(Dom to 11)
Dom
(Dom to 14)
Dom
(Dom to 27)
Mysore 24 668
(13 910 to 35 426)
517
(228 to 806)
2 207 376
(239 689 to 4 175 064)
Dom
(Dom to 37)
Dom
(Dom to 65)
Dom
(Dom to 49)
Dom
(Dom to 89)
Bellary 58 844
(15 034 to 102 654)
1244
(217 to 2271)
5 307 096
(–541 201 to 11 155 392)
Dom
(Dom to 4)
Dom
(Dom to 28)
Dom
(Dom to 25)
Dom
(Dom to 53)
Shimoga 12 403
(4134 to 20 672)
263
(62 to 465)
1 122 213
(–49 722 to 2 294 147)
Dom
(Dom to 34)
Dom
(Dom to 115)
Dom
(Dom to 55)
Dom
(Dom to 128)
Total 907 888
(716 689 to 1 099 086)
18 833
(14 435 to 23 232)
77 004 792
(52 809 309 to 101 200 276)
Dom Dom Dom Dom
Data are mean (SD 1·96). Dom=dominated (the intervention dominates the counterfactual where the intervention is on average less costly and more eﬀ ective than the counterfactual. Where there is no SD 
reported then the intervention dominates for all estimates within SD 1·96 of the mean.
Table 4: Eﬀ ect and cost eﬀ ectiveness, adjusted for future antiretroviral treatment cost
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The mean cost per DALY averted varied substantially by 
district, ranging between a mean incremental NGO cost 
per DALY averted of $4 and $122, and a mean 
incremental programme cost per DALY averted of $17 
and $471. In one district (Kolhapur) where condom use 
was high and increasing rapidly before Avahan, the 
uncertainty range in the cost per DALY averted was 
undeﬁ ned. In this district, condom use in the 
counterfactual scenario could be the same as in the 
intervention scenario, meaning that the number of 
infections averted would be zero, and hence the cost per 
DALY averted could be inﬁ nite.
The mean incremental programme cost per DALY 
averted declined to $36 when the time period was 
extended to 10 years, fell to $22 per DALY averted when 
DALYs were not discounted (table 3), and rose to $129 at 
an 8% discount rate (data not shown). Inclusion of ART 
costs resulted in an ART cost saving (for the lifetimes of 
the high-risk cohort of 154 425) of $77 004 792 (compared 
with the $50 533 660 spent on Avahan) in the 22 districts 
(table 4). Mean savings across the 22 districts that 
increased substantially as our assumptions about ART 
coverage increased (table 4). The ﬁ gure shows acceptability 
curves to represent the uncertainty in our estimates. 
Figure A shows the acceptability curves across all 
22 districts when ICERS in each district are assumed to 
have no correlation across districts. Figure B shows the 
acceptability curve when perfect correlation is assumed. 
Both results show that our estimates of cost-eﬀ ectiveness 
are robust, with 100% of sampled ICERS remaining well 
below the willingness-to-pay threshold.
Discussion
Our results conﬁ rm previous evidence from national 
models and pilot studies9,10 suggesting that HIV 
prevention programmes targeted at high-risk groups at 
scale are cost eﬀ ective (panel). Our estimates of 
incremental cost per DALY averted are substantially 
below the willingness-to-pay threshold and within the 
ranges achieved by other HIV preventive interventions.8,22 
Our ﬁ ndings therefore suggest that HIV prevention 
interventions focused on high-risk groups are good value 
for money in India and similar settings.
Our estimates of incremental cost per DALY averted 
are higher than those previously estimated for India.11 
This diﬀ erence is, to a large extent, due to the fact that we 
measured costs incurred above the NGO level in our 
analysis.7 These costs are important to consider because 
they are incremental and are likely to be a substantial 
component of the eﬀ ort to scale up HIV prevention 
rapidly, especially in any setting where NGO capacity is 
weak. We also found higher numbers of clients per FSW 
and more baseline condom use than in previous studies,10 
and a slower rate of increase in condom use, possibly 
reﬂ ecting the longer start-up period of larger scale 
programmes.5 Finally, we also chose a more conservative 
counterfactual than in previous studies.
Although our estimates of the incremental cost per 
DALY averted are higher than previous studies, the 
greater precision surrounding our estimates (primarily 
due to our extensive cost data collection, the ﬁ tting of 
the model, and use of in-depth local data from high-
quality surveys designed to parameterise the model), 
allows us to be more certain that targeted HIV 
prevention in India has been cost eﬀ ective. The 
remaining uncertainty we noted is largely due to the 
wide credibility interval we noted around the eﬀ ect 
estimates. This stems from the challenges of accurately 
mapping high-risk populations; the absence of baseline 
data for both condom use and HIV prevalence, which 
might be unavoidable in real-life evaluation of 
marginalised populations32 and which meant that 
condom trends were derived with additional uncertainty; 
and the relatively wide range of epidemic trajectories 
that could ﬁ t prevalence data at two or three timepoints.
We also noted a substantial variation in costs, eﬀ ect, 
and cost-eﬀ ectiveness by district. Although the few study 
sites means that statistical exploration of the drivers of 
this variation is challenging, complementary analyses of 
the costs from all Avahan districts show that both 
Figure: Probability that incremental programme cost per disability-adjusted 
life-year (DALY) averted is below willingness-to-pay (WTP) threshold for all 
22 districts (unadjusted for antiretroviral treatment [ART] costs)
(A) Assumes no correlation of mean ICERs across districts. (B) Assumes perfect 
correlation of mean ICERs across districts.
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programme scope and scale are key drivers of cost 
variation between districts.7 Speciﬁ cally, ongoing analysis 
suggests that the way in which programmes contract out 
STI services, the involvement of the community, and the 
type of FSW reached might explain the variation of costs 
between districts. We also note substantial economies of 
scale (with no diseconomies observed at high levels of 
coverage). HIV prevention programmes therefore have 
to carefully consider the size of the NGO contracted, 
weighing the beneﬁ ts of small community NGOs against 
the lower costs of larger NGOs that can beneﬁ t from 
economies of scale. Moreover, in our modelling work, we 
have identiﬁ ed several contextual factors that are likely to 
drive diﬀ erences in impact at the district level, such as 
the baseline level of condom use, the presence of other 
targeted HIV interventions and the size of the sex worker 
population.6 The eﬀ ect of these contextual factors means 
that care should also be taken before generalisation of 
our ﬁ ndings to other settings; these explanatory factors 
are also likely to vary by the stage of HIV epidemic 
and setting.
Although this study conﬁ rms that HIV prevention at 
scale can be highly cost eﬀ ective and potentially cost 
saving, several unresolved questions remain regarding 
the most aﬀ ordable model of scale-up. The costs shown 
here represent 22 districts, but are part of a wider costing 
study that has collected costs from 64 districts in India. 
From this broader costing study, we estimate that the 
annual cost of sustaining Avahan across four states is 
around $35 million.7 This is a sizeable sum, but remains 
a small proportion of the national health budget of 
around $5 billion per year.7 However, in view of recent 
budget cuts and the substantial disease burden in India, 
questions are being raised as to whether the Avahan HIV 
prevention model, with a high level of intensity support 
and community involvement, is the most cost-eﬀ ective 
way forward; and whether it is possible to achieve the 
same eﬀ ect with a lower scale or reduced scope of 
services. Further work is ongoing with the dataset we 
present to explore these questions, in particular to 
examine the eﬀ ect of increased investment in community 
mobilisation on HIV prevention programme cost-
eﬀ ectiveness, and threshold levels of coverage required 
to achieve a satisfactory eﬀ ect.
Finally, important limitations should be noted that 
aﬀ ect both our economic evaluation and those of most 
previous studies. First, our study excluded any economic 
welfare beneﬁ t to the recipients of HIV programmes by 
exclusion of other health and economic beneﬁ ts, such as 
DALY gains from reductions in violence, reductions in 
the number of cases of other STIs, reduced orphanhood 
from HIV, and other welfare gains for the increased 
empowerment of high-risk group members. Second, we 
excluded the costs incurred by the high-risk group 
members themselves, such as the opportunity cost of 
time spent with peer educators. Although the exclusion of 
costs incurred by high-risk group members could mean 
that we have overestimated cost-eﬀ ectiveness, these costs 
are likely to be small in view of the outreach nature of the 
Avahan programme. Third, compared with other Avahan 
districts, the 22 districts included in this study were more 
likely to have a pre-existing intervention and thus eﬀ ect 
and cost-eﬀ ectiveness might be lower than in other 
districts. Finally, our estimates of ART cost only included 
ﬁ rst-line treatment, so are likely to underestimate the true 
future resource requirements of ART.
This study provides evidence, with local data from a 
programme delivered to scale, that the large investment 
in targeted HIV prevention programmes made in India 
during the past decade has not only had an eﬀ ect, but has 
been cost eﬀ ective. To our knowledge, our ﬁ ndings are 
the best evidence so far to suggest that those responsible 
for HIV prevention programme development should 
consider sustaining and expanding investment in such 
programmes in India and beyond as a priority strategy 
for combating HIV.
Panel: Research in context
Systematic review
In 2009, a systematic review by Galarraga and colleagues8 
identiﬁ ed that few robust studies have assessed the cost 
eﬀ ectiveness of HIV prevention, with only a handful done in 
Asia, and that more than 25 years into the AIDS epidemic and 
billions of dollars of spending later, much work is still to be 
done both on costs and eﬀ ectiveness to adequately inform 
HIV prevention planning. Since then empirical research on 
the cost-eﬀ ectiveness for HIV prevention for high-risk groups 
has primarily either been further studies at a small scale, or 
has used national level data and models, requiring a large 
number of assumptions to be made.
Interpretation
Our work uses extensive primary data collection on costs and 
behavioural change in 22 districts in India, combined with a 
mathematical model of how this change aﬀ ects HIV 
transmission, to estimate the cost-eﬀ ectiveness of HIV 
prevention focused on high-risk groups at scale. It thus 
presents depth of empirically based estimates of cost 
eﬀ ectiveness without parallel globally. Our estimates of costs 
per disability-adjust life-year (DALY) averted are higher than 
those of previous studies of targeted HIV prevention,10 mainly 
because we included programme costs incurred above the 
service level, and noted higher numbers of clients per female 
sex workers, more baseline condom use, and a slower rate of 
increase in condom use than in previous studies.10 However, 
the greater precision surrounding our estimates allows us to 
conﬁ rm these previous estimates, with a robust empirical 
basis, and conclude that the large investment in targeted HIV 
prevention in India has been cost eﬀ ective in reducing HIV 
infection and is highly likely to be cost saving in the long run. 
Individuals working in HIV programmes in concentrated 
epidemic settings should therefore continue to invest (or 
expand investment) in HIV prevention for high-risk groups.
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